The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Retension Pharmaceuticals Appoints Alison Schecter As Chief Medical Officer and Alex Schwartz As Chief Financial Officer
PRIVATEMay 27, 2026•21 days ago
Position
Chief Financial Officer
Company
Retension Pharmaceuticals
Alex Schwartz
Falls ChurchBiotechnologyHealthcareHealth Care
Description
Retension Pharmaceuticals has announced the appointments of Alison D. Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer. These seasoned executives bring extensive clinical development and financial expertise to the company as it advances RTN-001 through its Phase 2b clinical trial.
Company Information
Company
Retension Pharmaceuticals
Location
Falls Church, Virginia, United States
About
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
Falls ChurchBiotechnologyHealthcareHealth Care